EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

A Multicenter National Study of AL Amyloidosis in China: Insights Into Real‐World Diagnosis, Treatment, and Prognosis

Jing Li, Chenqi Yu, Jinghua Wang, Ning An, Yujun Dong, Lijuan Chen iD, Jun Luo, Sili Wang iD, Quanyi Lu, Songfu Jiang, Jin Zhang, Yong Zou und 19 weitere

American Journal of Hematology · 2026-09 · 101 (9) · 2230-2245

DOI: 10.1002/ajh.70418 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift American Journal of Hematology, online erschienen am 23.06.2026. Verfasst von Jing Li und 30 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Immunoglobulin Light-chain Amyloidosis, Antibodies, Monoclonal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This national, multicenter, retrospective study analyzed 1070 patients with newly diagnosed systemic light‐chain (AL) amyloidosis in China (2008–2025). Findings reveal increasing annual diagnoses and a marked shift in first‐line therapy from proteasome inhibitor (PI)‐based regimens to predominantly daratumumab‐based regimens since 2024. Monthly kinetic assessments demonstrated that daratumumab‐based induction produced deeper and faster hematologic responses than PI‐based therapy [≥ very good hematologic partial response (HemVGPR): 80.3% vs. 70.8%, p = 0.012; median time to ≥ HemVGPR: 1.2 vs. 1.8 months, p = 0.001], with significantly superior cardiac overall response (63.1% vs. 53.3%, p = 0.030). Early mortality rates at 1, 3, and 6 months were 5.5%, 13.2%, and 16.2%, respectively, with daratumumab‐based therapy identified as an independent protective factor for 6‐month mortality. Median event‐free survival (EFS) was 44.4 months, while median overall survival (OS) was not reached. Achievement of hematologic complete response (HemCR) conferred superior EFS and OS over HemVGPR (both p < 0.001), with minimal residual disease negativity further improving EFS in HemCR patients ( p = 0.043). Concurrent hepatic and cardiac involvement defined a high‐risk subgroup with poor outcomes (median EFS 12.8 months, OS 51.0 months). Multivariable analysis confirmed Eastern Cooperative Oncology Group (ECOG) performance status (PS) > 2, liver involvement, and gain1q as adverse prognostic factors for EFS, whereas ≥ HemVGPR was protective. For OS, liver involvement, concomitant multiple myeloma, and ECOG PS > 2 were independent risk factors, while ≥ HemVGPR and cardiac response predicted improved survival. This study establishes a contemporary benchmark for AL amyloidosis management in China, confirming the superior real‐world efficacy of daratumumab‐based frontline therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunoglobulin Light-chain AmyloidosisAntibodies, MonoclonalHumansFemaleMaleChinaRetrospective StudiesPrognosisMiddle AgedAgedProteasome InhibitorsAdultAged, 80 and overSurvival Rate

Stichwörter der Autor:innen

daratumumabimmunoglobulin light‐chain amyloidosisprognosis

Substanzen

Antibodies, MonoclonaldaratumumabProteasome Inhibitors

Autor:innen und Institutionen

  • Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Department of Hematology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
  • Department of Hematology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • Department of Hematology, First Hospital of Peking University, Beijing, China.
  • Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
  • Department of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.

ORCID-Profile: Lijuan Chen, Sili Wang, Jihao Zhou, Chunrui Li, Peng Liu

Zitieren

APA

Li, J., Yu, C., Wang, J., An, N., Dong, Y., Chen, L., Luo, J., Wang, S., Lu, Q., Jiang, S., Zhang, J., Zou, Y., Shou, L., Shen, L., Chen, J., Zhang, L., Lu, X., Feng, J., Zhang, H., …, & Liu, P. (2026). A Multicenter National Study of AL Amyloidosis in China: Insights Into Real‐World Diagnosis, Treatment, and Prognosis. American Journal of Hematology, 101(9), 2230-2245. https://doi.org/10.1002/ajh.70418

Vancouver

Li J, Yu C, Wang J, An N, Dong Y, Chen L, et al. A Multicenter National Study of AL Amyloidosis in China: Insights Into Real‐World Diagnosis, Treatment, and Prognosis. American Journal of Hematology. 2026;101(9):2230-2245. doi:10.1002/ajh.70418

BibTeX
@article{Li2026,
  author = {Li, Jing and Yu, Chenqi and Wang, Jinghua and An, Ning and Dong, Yujun and Chen, Lijuan and Luo, Jun and Wang, Sili and Lu, Quanyi and Jiang, Songfu and Zhang, Jin and Zou, Yong and Shou, Lihong and Shen, Lin and Chen, Junmin and Zhang, Li and Lu, Xuzhang and Feng, Jia and Zhang, Hongyu and Jiang, Huifang and Zhou, Jihao and Xu, Tianhong and Wang, Wenjing and Yang, Yang and Zhou, Fanjie and Xie, Weiwei and Shen, Xuxing and Yang, Yang and Lai, Peilong and Li, Chunrui and Liu, Peng},
  title = {A Multicenter National Study of AL Amyloidosis in China: Insights Into Real‐World Diagnosis, Treatment, and Prognosis},
  journal = {American Journal of Hematology},
  year = {2026},
  volume = {101},
  number = {9},
  pages = {2230--2245},
  doi = {10.1002/ajh.70418}
}
Kostenlos starten →